Niramai Health Analytix, breast cancer screening startup receives seed funding

Published On 2017-04-26 04:24 GMT   |   Update On 2017-04-26 04:24 GMT

Niramai Health Analytix, a Bengaluru based breast cancer screening startup company has raised an undisclosed amount in seed funding from a group of investors including its early stage of investors led by Pi Ventures, Ankur Capital, Axilor Ventures, 500 Startups and Flipkart co-founder Binny Bansal.


NIRAMAI stands for "Non-Invasive Risk Assessment with Machine Intelligence." NIRAMAI developed a new cancer screening software that uses machine intelligence over thermography images to enable a low cost, easy to use, portable solution and requires minimal human supervision. NIRAMAI solution uses a high resolution thermal sensing device and cloud hosted analytics solution for analysing the thermal images.


It is reported that NIRAMAI will us these funds to strengthen its intellectual property portfolio, expand operations and make its cancer screening tool available for commercial use, said Geetha Manjunath, co-founder and chief executive of the firm said in the statement.


Manish Singhal, Founding Partner, Pi Ventures added, “Breast Cancer is a major killer across the world. In India, one out of two women die after getting diagnosed with breast cancer since the detection happens very late. Early detection is key to saving lives and is enabled very well with the innovative and disruptive AI based solution from NIRAMAI."


NIRAMAI was founded by former employees of Xerox Research Center and Hewlett-Packard Labs, Manjunath and Nidhi Mathur in July 2016.


Earlier this month, NIRAMAI also got selected to be a part of Axilor’s accelerator programme for the Summer 2017 batch.


 

 
Article Source : With inputs

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News